Axial Biotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
WALTHAM, Mass., September, 15, 2020 – Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that management will present at the H.C. Wainwright Annual Global Investment Conference on Tuesday, September 15, 2020 at 2:00 PM ET.
About Axial Therapeutics
Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurological diseases. Axial is advancing a pipeline of small molecule product candidates with lead clinical programs that address underlying pathology and resulting symptoms in Autism Spectrum Disorder (ASD) and Parkinson’s Disease (PD), and additional preclinical initiatives in small molecules in other areas of autism and PD, as well as oncology and rare CNS diseases.
Contacts for Axial Therapeutics
Sam Brown, Inc.
Jeffrey Young, CFO